Previous 10 | Next 10 |
Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference PR Newswire CINCINNATI , Jan. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials,...
Meridian Bioscience (NASDAQ:VIVO) says that its Chief Financial Officer and Executive Vice President Bryan Baldasare is retiring from the company effective Dec. 31, 2021. Baldasare, who joined Meridian (VIVO) in 2000, has served as its CFO since 2019. During his tenure, the company has expand...
Meridian Bioscience Announces Retirement of CFO Bryan Baldasare PR Newswire CINCINNATI , Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announce...
Meridian Bioscience (NASDAQ:VIVO) has announced that David Phillips, Chairman of the Board, will retire from the Board of Directors and not seek re-election when his term ends in Jan. 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the ...
Meridian Bioscience Announces Retirement of Chairman David Phillips PR Newswire CINCINNATI , Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, ann...
Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing PR Newswire CINCINNATI , Nov. 17, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider...
Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q4 2021 Earnings Call Nov 12, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Meridian Bioscience Inc (VIVO) Q4 2021 Earnings Call Transcript
Meridian Bioscience, Inc. (VIVO) Q4 2021 Earnings Conference Call November 12, 2021 10:00 AM ET Company Participants Charles Wood – Vice President of Investor Relations Jack Kenny – Chief Executive Officer Bryan Baldasare – Chief Financial Officer Conference Call Particip...
Meridian Bioscience (NASDAQ:VIVO): Q4 Non-GAAP EPS of $0.23 beats by $0.03; GAAP EPS of $0.15 misses by $0.04. Revenue of $76.2M (+18.8% Y/Y) beats by $7.8M. Shares +0.78% PM. Press Release For further details see: Meridian Bioscience EPS beats by $0.03, beats on revenue
Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance PR Newswire CINCINNATI , Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial r...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...